Gossamer Bio (GOSS) Q2 Earnings and Revenues Lag Estimates
https://www.zacks.com/stock/news/2320935/gossamer-bio-goss-q2-earnings-and-revenues-lag-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2320935
Aug 12, 2024 - Gossamer Bio (GOSS) delivered earnings and revenue surprises of -4.35% and 40.10%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
0
Bio-Rad (BIO) Faces Low BioPharma Demand, Competitive Pressure
https://www.zacks.com/stock/news/2320781/bio-rad-bio-faces-low-biopharma-demand-competitive-pressure?cid=CS-ZC-FT-analyst_blog|zer_report_update-2320781
Aug 12, 2024 - Bio-Rad (BIO) is experiencing weaker sales in Asia as China is currently entangled in a challenging research funding environment, and Japan, too, is facing constrained funding issues.
0
Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 91.69%: Read This Before Placing a Bet
https://www.zacks.com/stock/news/2320717/wall-street-analysts-think-q32-bio-qttb-could-surge-91-69-read-this-before-placing-a-bet?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2320717
Aug 12, 2024 - The consensus price target hints at a 91.7% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
0
Generation Bio Co. (GBIO) Reports Q2 Loss, Tops Revenue Estimates
https://www.zacks.com/stock/news/2318631/generation-bio-co-gbio-reports-q2-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2318631
Aug 07, 2024 - Generation Bio (GBIO) delivered earnings and revenue surprises of -14.81% and 26.85%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
0
Is the Options Market Predicting a Spike in 2seventy bio (TSVT) Stock?
https://www.zacks.com/stock/news/2316210/is-the-options-market-predicting-a-spike-in-2seventy-bio-tsvt-stock?cid=CS-ZC-FT-tale_of_the_tape|options-2316210
Aug 05, 2024 - Investors need to pay close attention to 2seventy bio (TSVT) stock based on the movements in the options market lately.
0
INmune Bio, Inc. (INMB) Q2 2024 Earnings Call Transcript
https://seekingalpha.com/article/4709572-inmune-bio-inc-inmb-q2-2024-earnings-call-transcript?source=feed_sector_transcripts
Aug 01, 2024 - INmune Bio, Inc. (NASDAQ:NASDAQ:INMB) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ETCompany ParticipantsDavid Moss - CFORaymond Tesi - CEO &...
0
Bio-Rad Laboratories, Inc. (BIO) Q2 2024 Earnings Call Transcript
https://seekingalpha.com/article/4709555-bio-rad-laboratories-inc-bio-q2-2024-earnings-call-transcript?source=feed_sector_transcripts
Aug 01, 2024 - Bio-Rad Laboratories, Inc. (NYSE:NYSE:BIO) Q2 2024 Earnings Conference Call August 1, 2024 5:00 PM ETCompany ParticipantsEdward Chung - Vice President of...
0
Instil Bio to in-license cancer candidates from ImmuneOnco
https://seekingalpha.com/news/4132497-instil-bio-stock-gains-licensing-deal?source=feed_sector_healthcare
Aug 01, 2024 - Instil Bio (TIL) stock gains as the company agrees to acquire ex-China rights to two cancer therapies from ImmuneOnco Biopharmaceuticals. Read more here.
0
Passage Bio gains after licensing deal with GEMMA Bio
https://seekingalpha.com/news/4132483-passage-bio-stock-gains-licensing-deal?source=feed_sector_healthcare
Aug 01, 2024 - Passage Bio (PASG) stock soars as the company out-licenses gene therapy programs targeting pediatric lysosomal storage diseases to GEMMA Biotherapeutics. Read more here.
0
Emergent Bio gains as RSDL sale nets $75M
https://seekingalpha.com/news/4131187-emergent-bio-stock-gains-rsdl-sale-nets-75m?source=feed_sector_healthcare
Jul 31, 2024 - Emergent Biosolutions (EBS) stock gains as the comany sells RSDL skin decontamination agent to SERB Pharmaceuticals for $75M. Read more here.
0